From: Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Agent | ET/Setting | Median PFS | HR | Trial |
---|---|---|---|---|
Palbociclib | Letrozole, 1st-line | 24.8 vs 14.5Â months | 0.58 | PALOMA-2 |
Palbociclib | Fulvestrant, 2nd-line | 9.2 vs 3.8Â months | 0.42 | PALOMA-3 |
Ribociclib | Letrozole, 1st-line | 25.3 vs 16.0Â months | 0.56 | MONALEESA-2 |
Abemaciclib | Fulvestrant, 2nd-line | 16.4 vs 9.3Â months | 0.55 | MONARCH-2 |